Nektar Therapeutics
NKTR Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$37.45
KIRA · Stoqly’s AI analyst, in plain words
- Nektar Therapeutics had $55.2M of revenue in fiscal 2025, down 43.9% on the year before. Over five years, revenue changed −18.4% a year on average.
- Its operating margin was −253.7%, down 146.8 pts: of every 100 in sales, about −254 is left after running the business.
- Nektar Therapeutics lost $164M in fiscal 2025.
- Free cash flow was −$209M in fiscal 2025, −377.8% of revenue.
- Nektar Therapeutics returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 23.0%.
Market cap
$1.2B
P/E
—
Revenue
$55.2M
Net income
−$164M
Free cash flow
−$209M
Operating margin
−253.7%
Nektar Therapeutics in 30 seconds · fiscal 2025
Are sales growing?
−43.9%
No. Sales fell 43.9% last year.
Does it make a profit?
−297.1%
No. It lost money last year.
Does profit turn into cash?
−377.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nektar Therapeutics does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- NEKTAR THERAPEUTICS
- CIK
- 0000906709
Nektar Therapeutics · NKTR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $102M | $92.1M | $90.1M | $98.4M | $55.2M |
| Revenue growth | −33.4% | −9.7% | −2.1% | 9.2% | −43.9% |
| Gross margin | 75.6% | 76.5% | 62.5% | 68.8% | 100.0% |
| Operating margin | −437.8% | −408.6% | −292.6% | −106.9% | −253.7% |
| Net income | −$524M | −$368M | −$276M | −$119M | −$164M |
| Net margin | −514.0% | −400.0% | −306.3% | −120.9% | −297.1% |
| Diluted EPS | −$2.86 | −$1.97 | −$1.45 | −$8.68 | −$9.73 |
| Cash | |||||
| Cash from operations | −$413M | −$304M | −$193M | −$176M | −$209M |
| Capital expenditure | $15.0M | $5.7M | $0.9M | $1.5M | $0.2M |
| Free cash flow | −$428M | −$310M | −$193M | −$177M | −$209M |
| FCF margin | −419.6% | −336.4% | −214.7% | −180.0% | −377.8% |
| Share buybacks | — | — | $0.0M | $3.0M | $0.0M |
| Share count change | 2.6% | 2.1% | 1.5% | −92.8% | 23.0% |
| Debt and strength | |||||
| Cash and short-term investments | $734M | $505M | $304M | $255M | $246M |
| Shareholders' equity | $680M | $367M | $131M | $60.7M | $89.8M |
| Current ratio | 9.3x | 8.0x | 6.5x | 4.3x | 5.0x |
| Returns and quality | |||||
| Return on equity | −59.6% | −70.4% | −110.9% | −124.1% | −217.9% |
| Return on tangible equity | −86.9% | −126.9% | −210.8% | −195.9% | −182.6% |
| Piotroski F-score | 1 | 3 | 2 | 4 | 2 |
| Altman Z'' | −5.1 | −12.7 | −27.8 | −36.3 | −41.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.4M
3 insiders
Of sales under plans
86%
$2.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nektar Therapeutics · NKTR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $37.45 a share, the company is worth $1.2B.
Source: SEC EDGAR XBRL filings (CIK 0000906709). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.